Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 4/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | RAC1 | P63000 | 4/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KMO | O15229 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | ACACA | Q13085 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3318714 | 0.99 | KDM4E (0.68) | KDM4EMAPTMEN1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL3318717 | 0.99 | KDM4E (0.68) | KDM4EMAPTMEN1KMT2ANPC1 | |
| SCHEMBL3320163 | 0.85 | KDM4E (0.76) | KDM4EMAPTMEN1KMT2ANPC1 | |
| SCHEMBL7822956 | 0.85 | KDM4E (0.83) | KDM4EMAPTMEN1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL3321733 | 0.84 | KDM4E (0.74) | KDM4EMAPTMEN1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL3321730 | 0.84 | KDM4E (0.74) | KDM4EMAPTMEN1KMT2ANPC1 | |
| SCHEMBL3321880 | 0.82 | KDM4E (0.80) | KDM4EMAPTMEN1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL3318463 | 0.81 | KDM4E (0.78) | KDM4EMAPTMEN1KMT2ANPC1 | |
| SCHEMBL3324961 | 0.81 | KDM4E (1.00) | KDM4EMAPTMEN1KMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL3318461 | 0.81 | KDM4E (0.78) | KDM4EMAPTMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2185521-A2 | COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES | Exonhit Therapeutics SA (FR) | 2010-05-19 | — | — | EP | disclosed |
| US-20100120810-A1 | COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES | EXONHIT THERAPEUTICS SA (FR) | 2010-05-13 | — | — | US | disclosed |
| US-20100120810-A1 | COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES | EXONHIT THERAPEUTICS SA (FR) | 2010-05-13 | — | — | US | disclosed |
| US-20100120810-A1 | COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES | EXONHIT THERAPEUTICS SA (FR) | 2010-05-13 | — | — | US | disclosed |
| WO-2009007457-A2 | COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES | EXONHIT THERAPEUTICS SA (FR) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009007457-A2 | COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES | EXONHIT THERAPEUTICS SA (FR) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120810-A1 | COMPOUNDS AND METHODS FOR MODULATING RHO GTPASES | RAC1, RAC2, RAC3 | KDM4E 3958/4885MAPT 2679/4885MEN1 2013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.